Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study

ObjectivesTo estimate the prevalence of children and adolescents reporting persistent symptoms after SARS-CoV-2 infection.DesignA random sample of children and adolescents participated with their family members to a serological survey including a blood drawing for detecting antibodies targeting the SARS-CoV-2 nucleocapsid (N) protein and a questionnaire on COVID-19-related symptoms experienced since the beginning of the pandemic.SettingThe study took place in the canton of Geneva, Switzerland, between June and July 2021.Participant660 children aged between 2 and 17 years old.Primary and secondary outcomeThe primary outcome was the persistence of symptoms beyond 4 weeks comparing seropositive and seronegative participants. The type of declared symptoms were also studied as well as associated risk factors.ResultsAmong seropositive children, the sex-adjusted and age-adjusted prevalence of symptoms lasting longer than 2 weeks was 18.3%, compared with 11.1% among seronegatives (adjusted prevalence difference (Delta aPrev)=7.2%, 95% CI: 1.5% to 13.0%). Among adolescents aged 12-17 years, we estimated the prevalence of experiencing symptoms lasting over 4 weeks to be 4.4% (Delta aPrev,95% CI: -3.8% to 13.6%), whereas no seropositive child aged 2-11 reported symptoms of this duration. The most frequently declared symptoms were fatigue, headache and loss of smell.ConclusionsWe estimated the prevalence of experiencing persistent symptoms lasting over 4 weeks to be around 4% among adolescents, which represents a large absolute number, and should raise awareness and concern. We did not observe meaningful differences of persistent symptoms between seropositive and seronegative younger children, suggesting that they may be less affected than their older counterparts.

Automated summary

This study aimed to estimate the prevalence of persistent symptoms among children and adolescents after SARS-CoV-2 infection. The results showed that the prevalence of symptoms lasting over 4 weeks among adolescents was estimated to be around 4%, which represents a large number and should raise awareness. There were no meaningful differences in persistent symptoms between younger children and their older counterparts.